Alzheimer's Disease
Conditions
Brief summary
The primary objective of this study was to evaluate the safety, tolerability and pharmacokinetic characteristics of single administration of AD16 tablets in healthy adults under fasting conditions, and the secondary objective was to preliminarily evaluate the material balance of single administration of AD16 tablets in fasting conditions. The study is divided into two parts: preliminary test and formal test. The formal trial was a single-center, randomized, placebo-controlled, double-blind, dose-increasing study, with 5 dose groups (5mg, 10mg, 20mg, 30mg and 40mg, respectively). Ten subjects (male and female) were enrolled in each dose group, of which 8 received the experimental drug and 2 received placebo. Urine and fecal samples were collected in the 20mg dose group for material balance study.Urine and fecal samples were collected in the 20mg dose group for material balance study.
Interventions
DRUGAD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg
Take one AD16 tablet in the morning
DRUGAD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg
Participants will take a placebo pill matching AD16 once in the morning
Sponsors
Xiangya Hospital of Central South University
South China Center For Innovative Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
A single-center, randomized, placebo-controlled, double-blind, dose-increasing study
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy subjects were aged 18-45 years (including boundary values), male and female. 2. Weight ≥50kg (male) or ≥45kg (female), and body mass index (BMI) of 19-24kg/m2 (including the boundary values at both ends). 3. Have fully understood this study, voluntarily participated in it, and signed the Informed Consent. 4. Subjects are able to communicate well with researchers and complete the study according to protocol. 5. The subjects were deemed to be in good health based on physical examination, medical history, vital signs, electrocardiogram, chest X-ray, abdominal ultrasound, and laboratory tests. 6. Subject (including partner) is willing to have no pregnancy plan for the next 30 days (female subject) or 90 days (male subject) and is willing to use effective contraception.
Exclusion criteria
1. Positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody or HIV antibody. 2. The patient has symptoms or related history of any serious disease, including but not limited to heart, liver, kidney, or other acute or chronic digestive tract or respiratory tract diseases, as well as diseases of the blood, endocrine, neurological, psychiatric and other systems, or any other disease or physiological condition that can interfere with the study results. 3. A history of postural hypotension with frequent episodes. 4. A history of frequent nausea or vomiting due to any cause. 5. Any clear history of drug or food allergies, especially allergies to ingredients similar to the drugs in this study. 6. Have special dietary requirements and cannot comply with the uniform diet provided by the clinical research center. 7. Previous drug abuse history or positive urine drug screening during screening period. 8. Smokers who smoked more than 5 cigarettes a day in the 3 months before the test. 9. Heavy drinkers or regular drinkers in the 6 months prior to the study screening, who drank more than 14 units of alcohol per week (1 unit of alcohol ≈360 mL beer or 45 mL 40% spirits or 150 mL wine) or had a positive alcohol breath test during the screening period. 10. Excessive consumption of tea, coffee (more than 6 cups) and/or caffeinated beverages (more than 1L) per day. 11. Surgical procedures, transfusions of blood or blood components in the month prior to study screening. 12. Blood loss or donation of more than 400 mL in the 2 months prior to screening. 13. Participated in other clinical studies and took experimental drugs within 3 months prior to study screening. 14. Study participants who had received any medication in the 28 days prior to screening. 15. Pregnant or lactating women or women who have had unprotected sex within 14 days. 16. Those unable to complete the study for other reasons or deemed unsuitable for inclusion by the researcher.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean retention time（MRT ）of AD16 | day1 to day3 | Mean retention time from first dosing to t hours or mean retention time from first dosing to infinity |
| CL/F of AD16 | day1 to day3 | CL/F is defined as the ratio of total clearance(CL) to bioavailability(F). administration |
| Vd/F of AD16 | day1 to day3 | Apparent volume of distribution after non-intravenous administration |
| λz of AD16 | day1 to day3 | Terminal disposition rate constant/terminal rate constant |
| Adverse events | day-7 to day3 | The number of adverse events |
| Serious adverse events | day-7 to day3 | The number of serious adverse events |
| Number of participants with abnormal laboratory test results | Screening period (day-7 to day-2) and day3 | Laboratory tests include Blood routine, blood biochemistry, coagulation function and urine routine |
| Number of participants with abnormal vital signs | day-7 to day3 | Pulse, blood pressure, body temperature and respiratory rate were observed at different time points before and after medication. |
| Number of participants with abnormal 12-lead electrocardiogram readings | Screening period (day-7 to day-2) and day3 | abnormal 12-lead electrocardiogram readings |
| Number of participants with abnormal physical examination findings | Screening period (day-7 to day-2) and day3 | The skin, mucosa, lymph nodes, head, neck, chest, abdomen, spine/limbs and nervous system were observed at different time points before and after medication. |
| Concomitant Medication | up to day3 | Any concomitant medication |
| Tmax of AD16 | day1 to day3 | Time to reach the maximum (peak) plasma concentration following drug administration |
| Cmax of AD16 | day1 to day3 | Maximum (peak) plasma drug concentration |
| t1/2z of AD16 | day1 to day3 | Elimination half-life (to be used in a one-compartment or noncompartmental model) |
| AUC 0-∞ of AD16 | day1 to day3 | AUC 0-∞ is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time). area under curve(AUC) |
| AUC 0-t of AD16 | day1 to day3 | AUC 0-t is defined as the concentration of drug from time zero to the last quantifiable concentration.area under curve(AUC) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fe0-t | day-3 to day3 | Cumulative excretion rate of drugs through urine Cumulative rate of drug excretion through feces |
| Renal clearance | day-3 to day3 | Renal clearance of drug from plasma |
| Ae | day-3 to day3 | The amount of drug excreted in urine at t hours after administration The amount of drug excreted by fecal sample at t hours after administration |
Countries
China
Outcome results
None listed